The University of Tennessee Research Foundation

The University of Texas System

The University of Mississippi

Bob M Moore, Ii

Suni Mustafa

Steven Gurley

Patrick Allison

Duane Douglas Miller

Himanshu Bhattacharjee

Gregory R Mundy

Laurence H Hurley

Sean Michael Kerwin

Charles Ryan Yates

Dennis R Feller

Antonio Ferreira

Leslie Stuart

Supriya A Bavadekar

Mathangi Krishnamurthy

Mark R DeLuca

Weiping Zheng

Cannabinoid derivatives according to formula (I) are disclosed wherein, X, Y, R, R, and W can have the definitions provided herein. Without limitation, use of such compounds, their salts or pro-drug, or compositions containing the compounds, salts, or pro-drug, to modify the activity of CB1 and CB2 receptors and treat conditions mediated by these receptors.

Tri-aryl/heteroaromatic cannabinoids and use thereof

Disclosed are compounds of the formula I: wherein R, R, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.

Pyridine non-classical cannabinoid compounds and related methods of use

Pyrimidine non-classical cannabinoid compounds and related methods of use

Furanopyridine cannabinoid analog compounds of the formula I are disclosed. The compounds are useful to modify the activity of CB1 and CB2 receptors and treat conditions mediated by these receptors.

Benzofuran cannabinoid compounds and related methods of use

Pyridine classical cannabinoid compounds and related methods of use

Furanopyridine cannabinoid analog compounds of the formula I are disclosed.  The compounds are useful to modify the activity of CB1 and CB2 receptors and treat conditions mediated by these receptors.

Furanopyridine cannabinoid compounds and related methods of use

Disclosed are compounds of the formula I: wherein R, R, V, W, X, Y and Z are as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors, such as, for example, inflammation.

Pyrimidine classical cannabinoid compounds and related methods of use

Yohimbine derivatives are disclosed having modification of the C-16 carboxyl group to include a sidechain and where the resulting derivative does not possess a second yohimbine pharmacophore (i.e., the compound is not a yohimbine dimer). The yohimbine derivatives of the present invention are preferably characterized by selective activity as &#x3b1;-AR antagonists. Use of the compounds, or pharmaceutical composition containing them, for treating or preventing an &#x3b1;adrenergic receptor mediated condition or disorder, and for antagonizing activity of an &#x3b1;adrenergic receptor are also disclosed.

Yohimbine derivatives and use thereof

1'-substituted cannabinoid derivatives of delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, and delta-6a-10a-tetrahydrocannabinol that have affinity for the cannabinoid receptor type-1 (CB-1) and/or cannabinoid receptor type-2 (CB-2). Compounds having activity as either agonists or antagonists of the CB-1 and/or CB-2 receptors can be used for treating CB-1 or CB-2 mediated conditions.

Cannabinoid derivatives, methods of making, and use thereof

Growing community of inventors

Nesbit, MS, United States of America

Bob M Moore, Ii